Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner

Hepatology

Volumn 59, Issue 4, 2014, Pages 1320-1330

  Fletcher, Nicola F ^a   Sutaria, Rupesh ^a   Jo, Juandy ^b   Barnes, Amy ^a   Blahova, Miroslava ^a   Meredith, Luke W ^a   Cosset, Francois Loic ^c   Curbishley, Stuart M ^a   Adams, David H ^a   Bertoletti, Antonio ^b   Mckeating, Jane A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AGENCY FOR SCIENCE   (Singapore)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; OCCLUDIN; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL STRAIN HEPG2; CONTROLLED STUDY; DIFFUSION COEFFICIENT; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INNATE IMMUNITY; KUPFFER CELL; LASSA VIRUS; LIVER CELL; MACROPHAGE ACTIVATION; MEASLES VIRUS; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; VIRUS ENTRY;

ANTIGENS, CD81; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL POLARITY; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES; OCCLUDIN; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS INTERNALIZATION;

EID: 84896494832     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26911     Document Type: Article

References (39)

1. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011;31(Suppl 1):68-77.
2. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011;53:1742-1751.
3. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012;22:182-193.
4. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opin Virol 2012;2:14-19.
5. Mee CJ, Harris HJ, Farquhar MJ, Wilson G, Reynolds G, Davis C, et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009;83:6211-6221.
6. Mee CJ, Grove J, Harris HJ, Hu K, Balfe P, McKeating JA. Effect of cell polarization on hepatitis C virus entry. J Virol 2008;82:461-470.
7. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
8. Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediat Inflamm 2012;2012:949157.
9. Heydtmann M. Macrophages in hepatitis B and hepatitis C virus infections. J Virol 2009;83:2796-2802.
10. Khakoo SI, Soni PN, Savage K, Brown D, Dhillon AP, Poulter LW, et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol 1997;150:963-970.
11. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000;46:260-269.
12. Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 2013;57:385-398.
13. Alabraba EB, Curbishley SM, Lai WK, Wigmore SJ, Adams DH, Afford SC. A new approach to isolation and culture of human Kupffer cells. J Immunol Methods 2007;326:139-144.
14. Cosset FL, Marianneau P, Verney G, Gallais F, Tordo N, Pecheur EI, et al. Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol 2009;83:3228-3237.
15. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003;100:7271-7276.
16. Harris HJ, Clerte C, Farquhar MJ, Goodall M, Hu K, Rassam P, et al. Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cell Microbiol 2013;15:430-445.
17. Jammart B, Michelet M, Pecheur EI, Parent R, Bartosch B, Zoulim F, et al. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol 2013;87:5065-5080.
18. Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown. Curr Opin Pharmacol 2009;9:715-720.
19. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013;9:e1003330.
20. Wei X, Jia ZS, Lian JQ, Zhang Y, Li J, Ma L, et al. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. J Interferon Cytokine Res 2009;29:171-178.
21. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201-213.
22. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133:1627-1636.
23. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011;141:1220-1230, 1230 e1221-1223.
24. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World Gastroenterol 2010;16:1321-1329.
25. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226-233.
26. Sourisseau M, Michta ML, Zony C, Israelow B, Hopcraft SE, Narbus CM, et al. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog 2013;9:e1003244.
27. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol 2007;120:1233-1244; quiz 1245-1236.
28. Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, Johnson LG. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 2002;13:3218-3234.
29. Harris HJ, Clerte C, Farquhar MJ, Goodall M, Hu K, Rassam P, et al. Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cell Microbiol 2012;15:430-435.
30. Petecchia L, Sabatini F, Usai C, Caci E, Varesio L, Rossi GA. Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest 2012;92:1140-1148.
31. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006;290:G496-504.
32. Lutschg V, Boucke K, Hemmi S, Greber UF. Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells. Nat Commun 2011;2:391.
33. El-Hage N, Dever SM, Fitting S, Ahmed T, Hauser KF. HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses. J Virol 2011;85:11601-11614.
34. Hassan M, Selimovic D, Ghozlan H, Abdel-Kader O. Induction of high-molecular-weight (HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell Signal 2007;19:301-311.
35. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50:1700-1711.
36. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-322.
37. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009;58:704-720.
38. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010;52:1829-1835.
39. Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 2011;74:522-547.